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ABSTRACT: Toxoplasmosis, while often an asymptomatic
parasitic disease in healthy individuals, can cause severe
complications in immunocompromised persons and during
pregnancy. The most common method to diagnose Toxoplasma
gondii infections is the serological determination of antibodies
directed against parasite protein antigens. Here we report the use
of a bead-based multiplex assay containing a synthetic
phosphoglycan portion of the Toxoplasma gondii glycosylphos-
phatidylinositol (GPI1) for the detection of GPI1-speciﬁc
antibodies in human sera. The glycan was conjugated to beads
at the lipid site to retain its natural orientation and its
immunogenic groups. We compared the response against GPI1
with that against the protein antigen SAG1, a common
component of commercial serological assays, via the detection of parasite-speciﬁc human IgG and IgM antibodies, respectively.
The GPI1-based test is in excellent agreement with the results for the commercial ELISA, as the ROC analysis of the GPI1 test
shows 97% speciﬁcity and 98% sensitivity for the assay. GPI1 was a more reliable predictor for a parasite-speciﬁc IgM response
compared to SAG1, indicating that a bead-based multiplex assay using GPI1 in combination with SAG1 may strengthen
Toxoplasma gondii serology, in particular in seroepidemiological studies.
Around one-third of the world’s population is chronicallyinfected by Toxoplasma gondii, a globally distributed
apicomplexan parasite that infects all warm blooded animals.1
Humans get infected with T. gondii mainly by ingesting raw or
undercooked meat from infected animals, by food contami-
nated with T. gondii oocysts,2 and rarely by organ transplants
from infected individuals.3 Generally, T. gondii infections in
healthy individuals are asymptomatic or induce only mild ﬂu-
like symptoms. In immunocompromised individuals T. gondii
infections can lead to serious complications such as
toxoplasmic encephalitis and/or ocular toxoplasmosis resulting
in blindness if not treated.4 Importantly, during pregnancy, a
primary infection with T. gondii can lead to transmission of the
parasites from mother to child, causing physical or mental
retardation of the infant or even induce abortion.4
T. gondii infections are primarily diagnosed by serological
detection of IgM and IgG antibodies, and in some cases IgA,
directed against parasitic protein antigens.5 Commercial assays
rely on antigens derived from whole T. gondii lysate, puriﬁed
from parasites grown in mice or cell culture, or from
recombinant sources.6,7 Antibodies are detected primarily by
immunochemical methods such as enzyme-linked immuno-
sorbent assay (ELISA), but indirect ﬂuorescent antibody test
(IFAT), immunosorbent agglutination assay (ISAGA), modi-
ﬁed agglutination tests (MAT), or indirect hemagglutination
assays (IHA) have also been used.7 These methods cannot
estimate the time point of the initial infection. In pregnant
women, the presence of IgM antibodies may mark a recently
acquired, acute infection. In this case, additional tests for IgG
and IgM avidity may be essential to determine whether the
infection occurred in a seronegative mother after conception
(primary infection). Thus, multiple assays are often used to
conﬁrm the infection but might also call for several
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conﬁrmatory tests by specialized diagnostic laboratories,8
requiring a larger volume of sera to be collected. In the case
of large-scale seroepidemiological studies access to serum is
limited, in particular from small children and in developing
countries.9−11 Determination of IgG and/or IgM responses
against several pathogens is desirable and also suﬃcient to
obtain estimates of prevalence of acute and chronic infections.
Therefore, assay formats allowing a parallel determination of
multiple analytes are ideal for these studies.
Bead-based multiplex assays (BBMAs) are high throughput
methods for the simultaneous detection and quantiﬁcation of
multiple analytes and samples.12 BBMAs use color-coded
beads that carry the antigen of interest. By addition of serum
samples, speciﬁc antibodies bind to the bead-coupled antigen,
which are detected using a secondary, ﬂuorescence-labeled
detection antibody (Figure 1a). A reader with two detection
channels separates the beads according to color code and
detects the intensity of the ﬂuorescent label on the secondary
antibody, respectively. This method is faster and requires less
sample than conventional methods to detect speciﬁc antibod-
ies.
Glycosylphosphatidylinositols (GPIs) are complex glycoli-
pids on the cell surface of eukaryotes that are present either in
protein-free form or used to anchor proteins to the cell
membrane. Two main GPI glycoforms are present on the
surface of T. gondii, a free GPI also known as the low molecular
weight antigen (GPI1),13 and GPI2 that anchors proteins such
as surface antigen SAG1 to the parasite membrane (Figure
1).14,15 Synthetic GPI glycans ﬁxed on array surfaces can be
used to detect IgG and IgM anti-GPI antibodies in sera from
infected individuals and to diﬀerentiate acute and latent
toxoplasmosis infections.16
Here we report the use of a synthetic GPI-glycan conjugated
to color-coded magnetic beads to detect anti-GPI1 antibodies
using a BBMA. This high-throughput method can simulta-
neously detect anti-SAG1 and anti-GPI1 antibodies with
diagnostic value for toxoplasmosis and enable large-scale
seroepidemiological studies.17 Furthermore, our data show
that comparing IgM responses directed against SAG1 and
GPI1 could allow the discrimination between acute and
postacute/latent infections.
■ MATERIALS AND METHODS
Serum Panel of Human Sera and Reference Measure-
ments for Analysis of Anti-T. gondii Antibodies. Serum
samples of anonymous donors were taken from a large
collection of human sera from the 1980s. These sera were
obtained during routine serosurveillance studies performed in
the former German Democratic Republic (now in possession
of the Robert Koch-Institute) and known to possess a high
proportion (>50%) of sera positive for anti-T. gondii
antibodies.18 These sera were sampled each year in 4−5
government districts (out of 15), collecting 150−200 samples
from 10 age groups (0 to >60 years). Sera were heat
inactivated. No further data are available. It has been shown
that even old sera still perform very well in serology, including
testing for T. gondii.19,20 Out of this collection, random
samples were picked and analyzed for the presence of anti-T.
gondii IgG antibodies using a commercial ELISA kit (Euro-
immun, Lübeck, Germany) following the supplier’s instruc-
tions. These sera are referred to as population-based panel
(PBP) sera. In addition, human sera from infected individuals
tested positive for anti-T. gondii IgM/IgG by routine diagnosis
using the VIDAS TOXO IgM or IgG (bioMeŕieux) enzyme-
linked ﬂuorescent immunoassays (ELIFA), scored positive
using the manufacturer’s recommended value for IgM (≥0.65)
or a cutoﬀ value of 8 IU/mL for IgG, were included. These
sera were classiﬁed as follows: (i) acute (1−3 months
postinfection (pi); high IgM concentrations and/or presence
of IgA antibodies and/or low IgG avidity and/or IFA ≥
1:1024), n = 7; (ii) postacute (>3 months pi; IgG avidity high
and/or IFA < 1:1024), n = 3; (iii) latent infection with IgM
persistence (low IgM concentrations or proven previous
infection >2 years, and/or high IgG avidity, and/or IFA <
1:1024), n = 6. No ethical clearance was necessary because
these serum samples were obtained for routine diagnosis and
used here without personalized data. Reference sera 13/13221
and 01/60022 were used for quantiﬁcation of anti-T. gondii IgG
in international units (IU) and were obtained from the
National Institute for Biological Standards and Control
(NIBSC), UK.
Synthetic GPI Phosphoglycan from T. gondii. The
phosphoglycan part of the glycosylphosphatidylinositol (GPI1)
from T. gondii was synthesized following established
protocols.23,24 A phosphate-alkyl-thiol linker replacing the
natural phospholipid was installed at the O-1 position of myo-
inositol and used for conjugation of the GPI1 glycan to
MagPlex beads modiﬁed with a maleimide (see below).
Glycan Microarray Detection of Anti-GPI Antibodies
Using Microarrays. Glycans were dissolved (ﬁnal concen-
tration of 250 μM) in phosphate buﬀer pH 7.4 including 250
μM of TCEP. The compounds were robotically printed onto
sciCHIP epoxy glass slides using the piezoelectric spotting
Figure 1. Detection of glycosylphosphatidylinositols of T. gondii
parasites. (a) Symbolic representation of the detection of anti-GPI
antibodies using the BBMA. (b) Chemical representation showing the
variations of T. gondii’s GPIs.
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device S3 (Scienion) at 50% relative humidity and 23 °C. The
preparation and analysis of sera were performed according to
previously established protocols.16 In brief, each serum sample
was diluted 1:15 with PBS (pH 7.4) containing 0.1% v/v
Tween 20 and 3% w/v BSA and incubated at 37 °C for 15 min
to dissolve potential lipid aggregates. The microarrays were
blocked with BSA (2.5%, w/v) in PBS for 1 h at room
temperature, washed twice with PBS and water, and dried by
centrifugation (3 min, 300g). The sera were added to the
microarrays and deposited in a sealed humidiﬁed incubator for
1 h at room temperature. Unbound sample components were
removed with a series of washes with 0.1% (1×) and twice with
0.001% v/v Tween 20 in PBS. The microarrays were incubated
for 1 h at room temperature with ALEXA-Fluor594 goat
antihuman-IgM antibody (μ-chain speciﬁc form; Life Tech-
nologies) or ALEXA-Fluor488 antihuman-IgG antibody (Fcγ
speciﬁc, from Dianova) diluted 1:400 in PBS containing 0.1%
v/v Tween 20 and 3% w/v BSA. The slides were washed (1×)
with PBS (pH 7.4) containing 0.1% v/v Tween 20 and 3% w/v
BSA, PBS (1×), and water (1×) and subsequently dried by
centrifugation (5 min, 300g). The slides were analyzed using a
ﬂuorescence microarray scanner (Genepix 4300A, Molecular
Devices) using a PMT gain that saturated the highest signals to
a minimum amount to ensure reproducibility. All analyzed
spots were manually adjusted and the “mean ﬂuorescence
values − background” was used for analysis.
Modiﬁcation of MagPlex Microspheres. Carboxyl-
functionalized MagPlex magnetic microspheres of region 20
(Luminex) were modiﬁed with a N-propylaminomaleimide
linker using the method described in the xMAP reference
book.25 Brieﬂy, 100 μL of the stock suspension (approximately
1.25 × 106 beads) of carboxyl-functionalized microspheres
were centrifuged and separated. The microspheres were
resuspended in 500 μL of 0.1 M 2-(N-morpholino)-
ethanesulfonic acid (MES) buﬀer pH 6.0, vortexed, sonicated
for 20 s, and pelleted with a magnet. The supernatant was
removed, the beads were resuspended in 100 μL of 0.1 M
MES, pH 6.0, containing 1 mg/mL of N-propylaminomalei-
mide (see SI for preparation), and 50 μL of a 10 mg/mL EDC
solution (freshly prepared in 0.1 M MES, pH 6.0) was added.
The microspheres were incubated for 2 h under continuous
mixing at room temperature. The reaction was quenched by
addition of 250 μL of 0.1 M MES, pH 4.5, and mixing. The
beads were pelleted, the supernatant was removed and the
microspheres were washed twice with 250 μL of 0.1 M MES,
pH 4.5. Finally, the microspheres were resuspended in 250 μL
of 0.1 M MES, pH 4.5, and stored at 4 °C in the dark or used
immediately for the coupling of the thiol linked glycan.
Coupling of Glycans to the Maleimide-Coupled
MagPlex Beads. The glycan disulﬁdes were reduced by
treatment with 1.1 equiv of resin-bound tris(2-carboxyethyl)-
phosphine (TCEP, Sigma-Aldrich) in 0.1 M PBS buﬀer (0.1M
sodium phosphate, 50 mM NaCl , pH 7.0). The resin was
removed, and the solution was lyophilized. Maleimide-
modiﬁed beads (1.25 × 106 microspheres) were washed with
0.1 M PBS and resuspended in 100 μL of the same buﬀer. A 50
μg amount of the freshly reduced GPI1 glycan was dissolved in
100 mM Tris buﬀer pH 7.4. The GPI1 solution was added to
the beads, and the ﬁnal volume was adjusted to 250 μL with
100 mM Tris buﬀer, pH 7.4. The reaction mixture was
incubated at room temperature in darkness. After 1 h, the
microspheres were pelleted and the supernatant was removed.
The unreacted maleimide groups were quenched by addition
of 100 μL of a 50 mM L-cysteine hydrochloride solution in 100
mM Tris buﬀer, pH 7.4. After 1 h, the microspheres were
pelleted, washed twice with 100 μL of 0.1 M PBS containing
1% BSA, and stored in 250 μL of 0.1 M PBS−TBN buﬀer at 4
°C.
Determination of the GPI1 Coupling Eﬃcacy to
MagPlex Beads. GPI-beads (5 × 105) were washed with
water and hydrolyzed using 200 μL of 2 M TFA for 4 h at 100
°C. The hydrolysis mixture was lyophilized, and the remainder
was dissolved in 100 mL of water and analyzed on a CarboPac
PA20 column (3 × 150 mm, Dionex) using a high-
performance anion exchange chromatography system coupled
with a pulsed amperometer detector (HPAE-PAD, Dionex,
Sunnyvale, CA). The monosaccharides were separated using
isocratic 10 mM NaOH (J.T. Baker, Devneter, The Nether-
lands) at 0.5 mL/min ﬂow rate for 15 min at 30 °C. The
quantity of GPI was calculated based on the content of glucose
in the injected samples. The amount of glucose was
determined using a calibration curve between 0 to 400 pmol
of the monosaccharide standards galactosamine, glucosamine,
and glucose (Sigma).
Coupling of Antihuman IgG, Human Serum Albumin
(HSA), and SAG1 Protein to MagPlex Beads. Carboxyl-
functionalized MagPlex beads (1.5 × 106 microspheres) of
regions 7 and 15 were transferred to an Eppendorf tube
(LoBind), washed with 100 μL of water, resuspended in 80 μL
of 100 mM NaH2PO4 buﬀer pH 6.2, mixed, and sonicated for
20 s. Sulfo-NHS (10 μL of 50 mg/mL) and EDC (10 μL of 50
mg/mL) were added, and the reaction mixture was incubated
for 20 min at room temperature under gentle mixing. The
microspheres were separated and resuspended in 100 μL of 50
mM MES pH 5.0 buﬀer and washed twice with the same
buﬀer. The activated microspheres were resuspended in 100
μL of 50 mM MES buﬀer and sonicated for 20 s, and then 20
μg of the corresponding protein, human serum albumin (HSA,
Sigma-Aldrich) or antihuman IgG (Fcγ speciﬁc, Dianova), was
added. The volume was adjusted to 500 μL with 50 mM MES
buﬀer, and the reaction mixture was incubated for 2 h under
mixing by rotation at room temperature. The beads were
separated, washed once with 500 μL and twice with 1 mL of
PBS−TBN buﬀer (PBS pH 7.3, 0.1% w/v BSA, 0.02% v/v
Tween 20, 0.05% w/v sodium azide), and ﬁnally stored in 500
μL of the same buﬀer at 4 °C. Coupling of T. gondii SAG1
protein (recombinantly expressed and puriﬁed in E. coli as
described26 but in biotinylated form) was performed via biotin
binding to recombinant streptavidin (AnaSpec, Fremont, CA),
which had been coupled to beads of region 33 (25 μg) as
described above. To this aim, a complete batch of SA-coupled
beads was suspended in 100 μL of PBS/BSA (0.1%) to which
10 μg of SAG1 was added. The beads were incubated
subsequently for 1 h at room temperature in a mixer at 600
rpm, washed twice with PBS/BSA (0.1%), and resuspended in
500 μL of PBS/BSA. After coupling, all beads were counted
using a counting chamber and adjusted to a concentration of
1000 beads/μL.
Detection of Anti-GPI Antibodies Using the Bead-
Based Multiplex Immunoassay. Successful determination
of anti-GPI antibodies was ﬁrst evaluated by incubation of the
loaded beads with T. gondii-positive reference sera, namely the
fourth IS WHO international standard 13/132 (containing 320
IU/mL anti-T. gondii IgG antibodies) and the WHO
International Standard anti-T. gondii IgG 01/600 (containing
20 IU/mL). The immunoassays were performed in 96-well
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plates (Greiner Bio-One) following recommendations in the
xMAP cookbook for serological assay.25 For quantiﬁcation, the
international standard 13/132 was used at a 1:4 dilution series
starting at a 1:200 dilution in PBS pH 7.3, 1% BSA (PBS-B)
assay buﬀer (seven dilutions total including a negative control
containing assay buﬀer only) while all sera were tested at a
1:200 dilution. The multiplex bead mix consisted of 1000
beads per bead region per well in 50 μL of assay buﬀer. First,
50 μL of the diluted standard and sera and 50 μL of bead mix
were added per well (GPI1 (region 20), SAG1 (region 33),
antihuman IgG (region 15) and HSA (region 7)). The plate
was incubated protected from light for 1 h at room
temperature under constant shaking at 600 rpm. Next, the
beads were washed with 2 × 200 μL of PBS-T (0.1% Tween
20) washing buﬀer using a magnetic plate washer (Tecan
HydroSpeed). To detect the bound antibodies, 100 μL of R-
phycoerythrin (PE)-coupled AﬃnityPure goat antihuman IgG,
Fcγ fragment speciﬁc or goat antihuman IgM, Fc5μ fragment
speciﬁc (both diluted to 1 μg/mL in assay buﬀer, both from
Dianova) was added, and the mixture was incubated protected
from light for 60 min as before. Subsequently, the beads were
washed with 3 × 200 μL of washing buﬀer and resuspended in
120 μL/well assay buﬀer before analysis using a Bio-Plex 200
system at normal detector gain. The mean ﬂuorescence
intensity (mﬁ) values for each sample and for each
microsphere in each well were determined using the Bio-Plex
Manager 6.1 software. Further data analysis was performed as
described below (see Data Analysis).
Data Analysis. All data analyses (plotting, quantiﬁcation,
and statistical analyses) were performed using the open source
statistics software R (version 3.5.1)27 in conjunction with the
following packages. Data from the Bio-Plex 200 were exported
to Microsoft Excel for subsequent import to R using the
package readxl which is contained within the tidyverse package.
A second Excel ﬁle containing metadata, such as plate layout
and concentrations of the standard 13/132 for quantiﬁcation,
was also imported to R and merged in a data frame suited for
subsequent analysis using the package drLumi.28 Here a
standard curve was generated for serum 13/132 using a ﬁve-
parameter nonlinear regression curve ﬁt of the mﬁ values over
international units with the negative control (buﬀer only) set
as constraint. Subsequently, the absolute concentration of
reactivity of the tested sera was expressed in international units
by calculation using this standard curve. To determine the
agreement between the results obtained by the multiplex assay
and the reference methods, the linear regression was calculated
between the log-transformed values of the quantiﬁed sera. The
positive and negative control beads were used to exclude sera
not fulﬁlling a quality control check (background binding to
HSA beads below 500 mﬁ (negative control) and binding to
antihuman IgG beads above 10 000 mﬁ (positive control))
from the analysis (83 sera were analyzed). A receiver−operator
curve was constructed using the pROC package.29 All plots
were generated using the ggplot2 package contained within the
tidyverse package. Finally, the agreement between the multiplex
assay and a reference ELISA for a small panel of IgM positive
sera (n = 20) was determined by calculating the Pearson’s
correlation coeﬃcient between the ELISA data (either
expressed in IU/mL or IgM index) and the mﬁ data.
Visualization of Figure 2 was performed with Prism 7
(GrapPad).
Figure 2. Binding of WHO reference sera 13/132 (a) or 01/600 (b) to GPI1-, SAG1-, HSA-, or antihuman IgG-coupled beads, respectively. IgG
antibodies were quantiﬁed by detection with goat antihuman IgG PE-coupled antibodies in a 4-plex assay. Comparison of results obtained by
glycan microarray and the BBMA (n = 19; mean of two independent experiments ± SD for the BBMA results). Shaded area indicates the
conﬁdence interval (95%). Comparison between ELISA and (a) SAG1 or (b) GPI1 used in the Bio-Plex assay for the quantiﬁcation of the anti-T.
gondii IgG immune response (n = 82 for SAG1 and 83 for GPI1). (c) Receiver−operator curves to determine sensitivity and speciﬁcity for
determination of T. gondii immune status by either GPI1 or SAG1 in comparison to the ELISA (cutoﬀ = 10 IU/mL). Bioplex results were
determined in two independent experiments (shown is mean ± SD). Shaded areas indicate 95% CI.
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■ RESULTS
Preparation of Glycans and Linkers. The glycan
portions of GPI1 and the mannose 3 were synthesized on
milligram scale following established protocols.23,24 To
conjugate the glycans to the carboxylate beads via a thiol, an
N-propylaminomaleimide (NPM) linker 5 was prepared in
80% yield and two steps: coupling of maleimide 4 with 3-(Boc-
amino)-1-propanol using Mitsunobu conditions (SI)30 fol-
lowed by Boc-group removal using TFA (Scheme 1).
Preparation of Glycan−Bead Conjugates. To establish
the best conditions for glycan conjugation, carboxylated
MagPlex microspheres (5 × 105 beads) were modiﬁed with
100 μL of linker 5 at 0.06, 0.16, 0.32, 0.65, and 1.30 mM
followed by reaction with 1.30 mM Man 3. Determination of
the Man3 conjugation eﬃciency with a solution of FITC-
labeled concanavalin A, a lectin-binding mannose, showed an
increase in ﬂuorescence for beads modiﬁed using between 6.5
and 65 nmol of the linker. Higher amounts (130 nmol) did not
increase the ﬂuorescence intensity, indicating saturation of the
binding sites on the microspheres (Figure S1, SI). On the basis
of this result, a 1 mg/mL (65 nmol/5 × 105 beads) solution of
linker 5 was used in all further experiments to modify the
microspheres. Then the GPI1 glycan was conjugated using 10
μg (6.6 nmol) of glycan/5 × 105 beads. Acid hydrolysis of the
GPI1 conjugate with TFA and further quantiﬁcation of glucose
using a HPAE-PAD chromatographic system showed a
coupling of 770 pmol/106 (1.16 μg of GPI1/106) beads
(SI). Analysis of a second conjugation of GPI1 to the beads
delivered a content of 1.36 μg of GPI1/106 beads, conﬁrming
the reproducibility of the conjugation and the determination.
Immunoreactivity of Coupled Antigens. To test the
applicability of GPI1 coupled to magnetic beads for the
detection of toxoplasmosis serostatus, a dilution series of
reference sera (starting at 1:200 dilution), positive for T. gondii
antibodies, was incubated with the 4-plex assay components
consisting of GPI1- and SAG1-loaded beads in addition to
HSA- and antihuman IgG-coupled beads (Figure 2a and 2b).
Both WHO reference sera were reactive against GPI1 and
Scheme 1. Preparation of Maleimide-Functionalized Beadsa
aReagents and conditions: (a) BocHN-(CH2)3-OH, PPh3, DIAD,
THF, rt, 48 h; (b) TFA, DCM, H2O, rt, 5 h, 80% (over two steps);
(c) MagPlex microspheres region 020, EDC, MES buﬀer pH 6.0; (d)
i. TCEP, PBS buﬀer pH 7.0, ii. Tris buﬀer pH 7.4
Figure 3. Correlation between IgG and IgM antibodies in a panel of 16 IgM-positive sera. Bio-Plex readout (mﬁ) vs ELIFA readout (IU or index)
are shown for IgG response (a, b) or IgM response (c, d), and GPI1 beads (a, c) or SAG1 beads (b, d), respectively. Results are based on two
independent experiments. Shaded areas indicate 95% CI.
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SAG1, with serum 13/132 exhibiting stronger binding to both
antigens when compared to serum 01/600, which agrees with
the higher content of T. gondii-speciﬁc antibodies. Binding to
SAG1, the immunodominant antigen during a T. gondii
infection,31 was higher for both reference sera as compared
to GPI1. However, GPI1 was also recognized by both sera in a
concentration-dependent manner and clearly above back-
ground binding to HSA.
Comparison of Microarrays and Bead Assay. Pre-
viously, we showed that GPI1 is a suitable antigen to detect
acute phase IgM antibodies in a microarray-based platform.16
Thus, we were interested to see whether those results could be
transferred to the BBMA. Detection of IgM antibodies using a
microarray and BBMA was performed with sera from 19
patients, acutely infected with T. gondii. Correlation of the anti-
GPI1 IgM antibody binding levels showed an excellent
agreement (linear regression R2 = 0.95) between both methods
(Figure 2c).
Validation of GPI1 and SAG1 Multiplex Assay
Performance for Serosurveys. Using the standardized
conditions, 88 human sera, previously characterized with a
commercial ELISA that is based on parasite lysate (PBP sera,
see Materials and Methods), were evaluated using the GPI1−
bead conjugate. To compare the potency of GPI1 glycan
against a protein marker, determination of the serostatus using
the BBMA assay was carried out using recombinant SAG126,32
conjugated to beads of region 33. Additionally, antihuman IgG
and human serum albumin (HSA) were included as positive
and negative control beads, respectively, and used to exclude
results that did not meet the quality criteria of mﬁ signals
>10 000 (antihuman IgG beads) and mﬁ signals <500 (HSA
beads) in two independent experiments. Additionally, results
were only valid if at least 50 independent events could be
evaluated per bead region. Using a standard curve generated by
ﬁtting a ﬁve-parameter nonlinear regression to a dilution series
of the WHO international reference standard 13/132, the
binding to both SAG1 and GPI1 beads was expressed in
international units (IU) per mL and compared to the results
obtained by the commercial ELISA for 82 (SAG1) or 83
(GPI1) sera by linear regression (Figure 2d and 2e). The
serostatus determined by IgG ELISA and the BBMA assay (R2
= 0.91 for SAG1; R2 = 0.66 for GPI1) was in very good
agreement.
On the basis of these data, the ability to discriminate in PBP
sera IgG-positive from -negative samples was determined for
both SAG1 and GPI1 by the multiplex assay in comparison to
the ELISA by receiver−operator curve (ROC) analysis. SAG1
allowed a perfect discrimination (area under curve = 1)
between positive and negative sera, while for GPI a clear
separation (few false positive or false negative samples) was
possible (area under curve = 0.98). Using a threshold of 20.6
IU/mL (95% CI 17.924.5), a maximum sensitivity of 97.1%
(95% CI 88.2100) was reached at a speciﬁcity of 98.0%
(95% CI 91.8100) for the analysis of IgG antibodies with
GPI1 as antigen (Figure 2f).
Analysis of Sera for IgM Antibodies. To compare the
BBMA results for both IgG and IgM with those from the
reference measurements performed by enzyme-linked ﬂuo-
rescent assay (ELIFA), a panel of 16 sera from IgM-positive
patients infected with T. gondii was analyzed. Correlation
analysis for the IgG response showed robust and signiﬁcant
correlation between the ELIFA data (expressed in IU/mL) and
the multiplex mﬁ results (Figure 3a,b) with Pearson’s
correlation coeﬃcients of 0.78 for SAG1 (p < 0.001) and
0.89 for the GPI1-conjugate (p < 0.0001). Interestingly, the
correlation between the BBMA and ELIFA data for IgM
measurement was signiﬁcantly higher for binding of acute sera
to GPI1 beads (correlation coeﬃcient of 0.9926, p = 0.0088),
while no correlation was detected between IgM against SAG1
and ELIFA (Figure 3c). However, IgM indices of sera from
postacute/latent infections correlated very well with IgM mﬁ
against SAG1 determined by BBMA (Figure 3d; correlation
coeﬃcient of 0.9232, p = 0.0038)). Although these data are
based on only a small number of sera, they showed a
diﬀerential response against the two deﬁned antigens for
discriminating very early from later infections.
■ DISCUSSION
Protozoan parasites are characterized by the presence of many
free and protein-attached GPIs on the surface of the cell
membrane.33 These glycolipids are potent modulators of the
host immune system during infections and induce the
production of antiglycan antibodies.34 T. gondii displays two
GPIs on the cell membrane that diﬀer by the presence of a
glucose unit in the glycan branch and the mode of
presentation. The GPI containing glucose, also known as the
low molecular weight antigen (LMWA), is found only as free
glycolipid and is a strong activator of the host immune
system.13 Previously, we demonstrated the presence of speciﬁc
antibodies against this glycolipid in sera from T. gondii-infected
individuals that can be used to determine the infection and the
relevance of the glucose residue for the diﬀerentiation of anti-
GPI antibodies.23 Using the synthetic phosphoglycan GPI1
printed on microarrays and a set of reference sera a test was
developed to detect seropositive sera and to diﬀerentiate the
acute and latent stages of a T. gondii infection.16
To evaluate the potential of synthetic GPI1 for the
determination of the T. gondii serostatus in humans using a
BBMA, we ﬁrst established the conjugation of the antigen to
carboxylate microspheres. Various strategies for coupling
glycan structures to carboxyl-functionalized beads have been
described, e.g., via end-biotinylated ABO blood group glycans
to streptavidin-coated beads,35 by functionalization of
pneumococcal polysaccharides with 4-(4,6-dimethoxy[1,3,5]-
triazin-2-yl)-4-methyl-morpholinium (DMTMM) before add-
ing to beads,36 or more classically by standard carbodiimide-
based coupling protocols for glycans with a terminal amine
group.37−39 However, in the case of GPI1, the free amine
groups of glucosamine and phosphoethanolamine are
important for the speciﬁc binding of antibodies to GPIs.16,40
Thus, we selected a conjugation method using maleimide-
activated beads and reaction with a thiol linker that is attached
at the phospho-myo-inositol unit of GPI1 to retain the natural
orientation of the glycan. Initial conjugation of the maleimide
beads with a test compound (Man3) showed a concentration
dependency and saturation of the binding sites using 65 nmol
of Man3 per 105 beads. Considering the complexity, value, and
size of GPI1, this glycan was conjugated using 6.5 nmol/105
beads to get a loading of 1.1 μg of GPI1/106 beads. This
loading was in line with the theoretical capacity of the beads
(108 active sites/bead) and was reproducible between two
diﬀerent batches (SI).
Next, we established the use of the GPI1−bead conjugate
for anti-GPI antibodies detection using BBMA in three steps.
First, the detection of anti-GPI1 antibodies in the 13/132 and
01/600 WHO reference sera was used to determine the
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immunoreactivity of the GPI-conjugate to distinguish sero-
positive samples. Then the detection of anti-GPI antibodies by
BBMA was compared with the detection on microarrays using
19 characterized sera, and ﬁnally the BBMA was compared
with a commercial ELISA test using a larger number of
samples. The ﬁrst two analyses showed good correlation and
translation from microarrays to BBMA for both IgG and IgM
anti-GPIs antibody detection and the possibility to quantify the
immunoreactivity of the GPI-conjugates against established
standards, which is required for proper standardization of the
method.6 Antibody detection was performed using the full
glycan of the LMWA (GPI1). Previously, we showed the
detection of anti-GPI antibodies on microarrays using
fragments of GPI1 with similar speciﬁcity as with the full
glycan.16 These smaller fragments represent an alternative to
GPI1 to use deﬁned material with reduced complexity and
production cost of the antigen without loss of speciﬁcity and
selectivity in the assay.
The detection of anti-GPI1 IgM and IgG antibodies in sera
from acute infected patients showed the induction of these
antibodies at the initial stage of the infection.34 However, the
detection of IgG serostatus by BBMA of >80 sera using GPI1
presented a lower correlation with the commercial ELISA test
than BBMA using SAG1 as antigen. The correlation diﬀerence
could derive from the sole usage of SAG1, which is the main
immunogenic protein on the surface of tachyzoites31 and a low
abundance or absence of the LMWA in the detergent extract of
puriﬁed T. gondii parasites used as antigen in the commercial
ELISA test.
The detection of antiglycan antibodies in ovarian cancer
patients by three glycan immunoassays (ELISA, printed glycan
array, and BBMA assay) has shown variable detection
speciﬁcities that are inﬂuenced by factors such as density,
surface presentation of glycans, and antibody/antigen ratios for
each assay format.41 Therefore, each assay format has its own
advantages and disadvantages. BBMA is suitable for diagnostic
purposes in clinical settings, illustrated by the recently
introduced commercial multiplex assay for the detection of
IgM antibodies against T. gondii, rubella, and cytomegalovirus
(ToRC)42−44 or for large-scale epidemiological surveys.10,45
We illustrate that the GPI1 glycan antigen works independ-
ently of the type of assay used and can be applied for the
detection of both IgG and IgM antibodies, which might be a
valuable addition to established commercial assays. Further
studies should determine the reactivity of IgA and IgE
antibodies, and the avidity of IgG antibodies toward GPIs,
which may extend the applicability of this antigen to conﬁrm
an acute infection also in other assay formats. Moreover, the
possibility of discrimination of very early from later infections
by using SAG1 and GPI1 as antigens and combined with IgM
serology needs to be substantiated with sera from a larger panel
and also from diﬀerent patient cohorts (immunocompromised
patients, newborns from seropositive mothers, follow-up sera
from the same seroconverters, etc.).
■ CONCLUSION
Synthetic glycan antigen GPI1 from T. gondii was conjugated
to maleimide-modiﬁed carboxylate-beads to determine the
anti-T. gondii serostatus using a bead-based multiplex assay.
GPI1 was only slightly less sensitive and speciﬁc in detecting
IgG antibodies in human sera than the protein antigen SAG1.
However, GPI1 was better than SAG1 in detecting the IgM
immune response during an early acute infection. Therefore,
GPI1 is an attractive candidate antigen to be included in
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